Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31truefalse2024-01-01falseResearch and experimental development on biotechnology3333trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 12294967 2024-01-01 2024-12-31 12294967 2023-01-01 2023-12-31 12294967 2024-12-31 12294967 2023-12-31 12294967 c:Director2 2024-01-01 2024-12-31 12294967 d:FurnitureFittings 2024-01-01 2024-12-31 12294967 d:FurnitureFittings 2024-12-31 12294967 d:FurnitureFittings 2023-12-31 12294967 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 12294967 d:OfficeEquipment 2024-01-01 2024-12-31 12294967 d:OfficeEquipment 2024-12-31 12294967 d:OfficeEquipment 2023-12-31 12294967 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 12294967 d:ComputerEquipment 2024-01-01 2024-12-31 12294967 d:ComputerEquipment 2024-12-31 12294967 d:ComputerEquipment 2023-12-31 12294967 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 12294967 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 12294967 d:CurrentFinancialInstruments 2024-12-31 12294967 d:CurrentFinancialInstruments 2023-12-31 12294967 d:Non-currentFinancialInstruments 2024-12-31 12294967 d:Non-currentFinancialInstruments 2023-12-31 12294967 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 12294967 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 12294967 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 12294967 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 12294967 d:ShareCapital 2024-12-31 12294967 d:ShareCapital 2023-12-31 12294967 d:OtherMiscellaneousReserve 2024-12-31 12294967 d:OtherMiscellaneousReserve 2023-12-31 12294967 d:RetainedEarningsAccumulatedLosses 2024-12-31 12294967 d:RetainedEarningsAccumulatedLosses 2023-12-31 12294967 c:OrdinaryShareClass1 2024-01-01 2024-12-31 12294967 c:OrdinaryShareClass1 2024-12-31 12294967 c:OrdinaryShareClass1 2023-12-31 12294967 c:FRS102 2024-01-01 2024-12-31 12294967 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 12294967 c:FullAccounts 2024-01-01 2024-12-31 12294967 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 12294967 d:WithinOneYear 2024-12-31 12294967 d:WithinOneYear 2023-12-31 12294967 d:BetweenOneFiveYears 2024-12-31 12294967 d:BetweenOneFiveYears 2023-12-31 12294967 2 2024-01-01 2024-12-31 12294967 6 2024-01-01 2024-12-31 12294967 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 12294967









OCHRE BIO LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
OCHRE BIO LTD
REGISTERED NUMBER: 12294967

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

FIXED ASSETS
  

Tangible assets
 4 
471,814
1,424,616

Investments
 5 
1,039,666
1,039,666

  
1,511,480
2,464,282

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 6 
5,871,030
2,604,460

Cash at bank and in hand
  
5,799,466
2,191,622

  
11,670,496
4,796,082

Creditors: amounts falling due within one year
 7 
(8,599,768)
(1,342,649)

NET CURRENT ASSETS
  
 
 
3,070,728
 
 
3,453,433

TOTAL ASSETS LESS CURRENT LIABILITIES
  
4,582,208
5,917,715

Creditors: amounts falling due after more than one year
 8 
(8,645,654)
(4,196,264)

  

NET (LIABILITIES)/ASSETS
  
(4,063,446)
1,721,451


CAPITAL AND RESERVES
  

Called up share capital 
 9 
82
82

Other reserves
  
27,281,483
27,281,483

Profit and loss account
  
(31,345,011)
(25,560,114)

  
(4,063,446)
1,721,451


Page 1

 
OCHRE BIO LTD
REGISTERED NUMBER: 12294967
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Q Wills
Director

Date: 30 September 2025

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


GENERAL INFORMATION

Ochre Bio Limited is a private company limited by shares and incorporated in England and Wales. Its registered office address is Hayakawa Building, Oxford Science Park, Edmund Halley Road, Oxford, England, OX3 7FZ.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

 
2.3

TURNOVER

Turnover comprises revenue recognised by the Company in respect of services supplied during the period, exclusive of Value Added Tax.

 
2.4

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 3

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)


2.4
TANGIBLE FIXED ASSETS (CONTINUED)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Research equipment
-
3 years straight line
Office equipment
-
3 years straight line
Computer equipment
-
3 years straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

VALUATION OF INVESTMENTS

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.6

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.10

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.11

OPERATING LEASES

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.12

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.13

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.14

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:
- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.
Deferred tax balances are not recognised in respect of permanent differences. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date. 

Page 5

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 33 (2023 - 33).


4.


TANGIBLE FIXED ASSETS





Fixtures and fittings
Office equipment
Computer equipment
Total

£
£
£
£



COST OR VALUATION


At 1 January 2024
3,583,290
7,994
99,547
3,690,831


Additions
163,240
-
19,281
182,521


Disposals
(3,532)
-
(971)
(4,503)



At 31 December 2024

3,742,998
7,994
117,857
3,868,849



DEPRECIATION


At 1 January 2024
2,194,774
4,553
66,888
2,266,215


Charge for the year on owned assets
1,101,862
2,569
27,306
1,131,737


Disposals
-
-
(917)
(917)



At 31 December 2024

3,296,636
7,122
93,277
3,397,035



NET BOOK VALUE



At 31 December 2024
446,362
872
24,580
471,814


5.


FIXED ASSET INVESTMENTS





Investments in subsidiary companies

£



COST OR VALUATION


At 1 January 2024
1,039,666



At 31 December 2024
1,039,666




Page 6

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
2023
£
£


Trade debtors
4,168,848
-

Other debtors
61,828
167,082

Prepayments and accrued income
140,354
228,718

Tax recoverable
1,500,000
2,208,660

5,871,030
2,604,460



7.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
2023
£
£

Trade creditors
854,312
284,871

Amounts owed to group undertakings
308,121
733,932

Other taxation and social security
350,400
83,732

Other creditors
25,385
28,484

Accruals and deferred income
7,061,550
211,630

8,599,768
1,342,649


Other creditors include contributions of £24,005 (2023 - £23,283) payable to the Company's defined contribution scheme at the balance sheet date. 


8.


CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2024
2023
£
£

Other loans
-
4,196,264

Amounts owed to group undertakings
4,010,680
-

Accruals and deferred income
4,634,974
-

8,645,654
4,196,264


Page 7

 
OCHRE BIO LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9.


SHARE CAPITAL

2024
2023
£
£
ALLOTTED, CALLED UP AND FULLY PAID



820,000 (2023 - 820,000) Ordinary shares shares of £- each
82
82



10.


COMMITMENTS UNDER OPERATING LEASES

At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£



Not later than 1 year
123,981
170,752

Later than 1 year and not later than 5 years
-
-

 
Page 8